A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.

Trial Profile

A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 15 May 2017

At a glance

  • Drugs Durvalumab (Primary) ; Tremelimumab (Primary) ; Carboplatin; Etoposide; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel; Paclitaxel
  • Indications Breast cancer; Fallopian tube cancer; Gastric cancer; Head and neck cancer; Oesophageal cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 11 May 2017 Planned End Date changed from 29 May 2018 to 1 Jul 2019.
    • 11 May 2017 Planned primary completion date changed from 29 May 2018 to 1 Jul 2019.
    • 06 Apr 2017 Status changed from active, no longer recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top